ClinicalTrials.gg
CompletedNCT01001377Updated Sep 21, 2022Results posted

ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

A Phase 3 interventional study of Cetuximab and Panitumumab in Metastatic Colorectal Cancer, sponsored by Amgen. Completed at 152 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-21.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,010
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 90 studies testing panitumumab in Colorectal Neoplasms — 7 open to participants now, 12 under way, 3 of them phase 3. Panitumumab · Colorectal Neoplasms.

Enrollment
6th of 88
1,010 · median 70
Started
2010
with 9 others
Phase 3
14 of 90
2 open now
Registered
35th of 90
by date
Lead sponsor
20 of 90
Amgen

Among the 90 studies testing panitumumab in Colorectal Neoplasms, this one is the 6th largest by enrollment of the 88 interventional ones that give a count, is one of 10 that started in 2010, is one of 14 in phase 3, and was the 35th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

7 of the 90 studies testing panitumumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About panitumumab

Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing panitumumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The primary objective of this study is to compare the effect of panitumumab versus cetuximab on overall survival (OS) for chemorefractory metastatic colorectal cancer (mCRC) among patients with wild-type Kirsten rat Sarcoma-2 virus (KRAS) tumors.

03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • Panitumumab
  • Vectibix
  • Colon Cancer
  • Colorectal Cancer
  • Rectal Cancer
  • Cetuximab
  • Erbitux
  • Metastatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of adenocarcinoma of the colon or rectum, disease
  • Wild-type KRAS tumor status
  • (ECOG) score of 0, 1 or 2
  • Must have failed a prior regimen containing irinotecan for metastatic disease and a prior regimen containing oxaliplatin for metastatic disease
  • Must have previously received a thymidylate synthase inhibitor (eg, fluorouracil, capecitabine, raltitrexed, or fluorouracil-uracil) at any point for treatment of colorectal cancer (CRC)
  • Adequate hematologic, renal, hepatic and metabolic function

Exclusion criteria

Exclusion Criteria:

  • Symptomatic requiring treatment
  • Prior anti-epidermal growth factor receptor (EGFr) antibody therapy (eg, panitumumab or cetuximab) or treatment with small molecule EGFr inhibitors (eg, gefitinib, erlotinib, lapatinib)
  • Antitumor therapy (eg, chemotherapy, hormonal therapy, immunotherapy, antibody therapy, radiotherapy), or agent or therapy ≤ 30 days before randomization.
  • cardiovascular disease
  • Active infection requiring systemic treatment or any uncontrolled infection ≤14 days prior to randomization
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,010 participants (actual)

Study arms

  • Active comparator
    Cetuximab

    Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days. Participants were treated until disease progression, intolerability, withdrawal of consent, or death.

    Drug: Cetuximab

  • Experimental
    Panitumumab

    Panitumumab 6 mg/kg IV every 14 days. Participants were treated until disease progression, intolerability, withdrawal of consent, or death.

    Drug: Panitumumab

Interventions

  • Administered by intravenous infusion

    Also known as: Erbitux

  • Administered by intravenous infusion

    Also known as: Vectibix

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall survival is the time from the date of randomization until the date of death. Participants who had not died by the analysis data cut-off date were censored at their last contact date.

    Time frame: From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.

Secondary outcomes

  1. Progression-free Survival

    Progression free survival (PFS) is the time from the date of randomization to the date of disease progression per the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or death. Participants alive and not meeting criteria for progression by the analysis data cut-off date were censored at their last evaluable disease assessment date. Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study based on all target lesions recorded since the treatment started (the sum must also demonstrate an absolute increase of at least 5 mm), or unequivocal progression of existing non-target lesions, or any new lesions.

    Time frame: From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.

  2. Objective Response

    Objective response is either a complete response (CR) or partial response (PR) per RECIST version 1.1. All participants that did not meet the criteria for an objective response by the analysis cut-off date were considered non-responders. CR: Disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and disappearance of all non-target lesions, and no new lesions. PR: Disappearance of all target lesions, persistence of one or more non-target lesions not qualifying for either CR or progressive disease, or, at least a 30% decrease in the sum of diameters of target lesions with no unequivocal progression of existing non-target lesions and no new lesions.

    Time frame: From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.

  3. Duration of Response

    Duration of response (DOR), calculated only for those participants with an objective response, is the time from first objective response to disease progression per the RECIST v1.1 or death. Participants not meeting criteria for progression or who died by the analysis data cutoff date were censored at their last evaluable disease assessment date.

    Time frame: From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.

  4. Time to Response

    Time to response (TTR), calculated for those participants with an objective response, is defined as the time from the randomization date to the date of first objective response.

    Time frame: From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.

  5. Time to Treatment Failure

    Time to treatment failure (TTF) is the time from randomization date to date that the decision was made to end the treatment period for any reason; participants who remained in the treatment period at the time of analysis were censored at the date of the last on-study assessment.

    Time frame: From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.

  6. Change From Baseline in EuroQOL 5 Dimension (EQ-5D) Health State Index Score

    The EQ-5D is a standardized instrument for use as a generic measure of health outcome. The health state index measures the following 5 health dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension contains 3 levels of response to reflect degree of problems participants have experienced: no problem (1), some problem (2) and extreme problems (3). The health states for each respondent are converted into a single index number using a specified set of weights. Resulting scores can range from 1.0 and -0.594. A higher score indicates a more preferred health status with 1.0 representing perfect health and 0 representing death. Negative scores are possible and represent health states regarded as less preferable than death (0). Repeated measures mixed model includes treatment, geographic region, ECOG score, assessment week, and treatment by assessment week interaction as fixed effects, and participants a random effect.

    Time frame: From Study Day 1 through the last day of treatment or disease progression, up to Week 85.

  7. Change From Baseline in EuroQOL 5 Dimension (EQ-5D) Visual Analog Scale (VAS)

    The EQ-5D is a standardized instrument for use as a generic measure of health outcome. The VAS asks respondents to rate their present health status on a 0 - 100 scale, with 0 labeled as "Worst imaginable health state" and 100 labeled as "Best imaginable health state." The VAS score is determined by observing the point at which the participant's hand drawn line intersects the scale.

    Time frame: From Study Day 1 through the last day of treatment or disease progression, up to Week 85.

  8. Change From Baseline in National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Colorectal Symptom Index (NCCN FCSI ) Symptoms Score

    The FCSI consists of 9 questions comprising the most important symptoms associated with colorectal cancer, including energy, pain, weight, diarrhea, nausea, swelling or cramps in the stomach area, appetite, ability to enjoy life, and overall quality of life. The 9 questions are combined in three algorithms to provide information for 3 domains: colorectal cancer symptoms, physical well-being, and functional well-being. Each of the 9 items are scored from "0" to "4" representing "Not at All" through to "Very Much True". The raw score for all items is transformed to a 0-100 scale, and the average for each of the 3 subscales is calculated; high scores illustrate an improved state (e.g. able to enjoy life more).

    Time frame: From Study Day 1 through the last day of treatment or disease progression, up to Week 85.

  9. Change From Baseline in NCCN FCSI Physical Well-being Scale Score

    The FCSI consists of 9 questions comprising the most important symptoms associated with colorectal cancer, including energy, pain, weight, diarrhea, nausea, swelling or cramps in the stomach area, appetite, ability to enjoy life, and overall quality of life. The 9 questions are combined in three algorithms to provide information for 3 domains: colorectal cancer symptoms, physical well-being, and functional well-being. Each of the 9 items are scored from "0" to "4" representing "Not at All" through to "Very Much True". The raw score for all items is transformed to a 0-100 scale, and the average for each of the 3 subscales is calculated; high scores illustrate an improved state (e.g. able to enjoy life more).

    Time frame: From Study Day 1 through the last day of treatment or disease progression, up to Week 85.

  10. Change From Baseline in NCCN FCSI Functional Well-being Scale Score

    The FCSI consists of 9 questions comprising the most important symptoms associated with colorectal cancer, including energy, pain, weight, diarrhea, nausea, swelling or cramps in the stomach area, appetite, ability to enjoy life, and overall quality of life. The 9 questions are combined in three algorithms to provide information for 3 domains: colorectal cancer symptoms, physical well-being, and functional well-being. Each of the 9 items are scored from "0" to "4" representing "Not at All" through to "Very Much True". The raw score for all items is transformed to a 0-100 scale, and the average for each of the 3 subscales is calculated; high scores illustrate an improved state (e.g. able to enjoy life more).

    Time frame: From Study Day 1 through the last day of treatment or disease progression, up to Week 85.

  11. Number of Participants With Adverse Events (AEs)

    Serious adverse events include any event that is fatal, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or other significant medical hazard. Treatment-related AEs are those the investigator considered as a reasonable possibility to have been caused by study drug.

    Time frame: From the day of the first dose of study therapy through 30 days since the last dose. Maximum time on study treatment was 130 weeks.

07

Results

Posted Mar 24, 2014

Participant flow

First patient enrolled on 2nd February 2010 and last patient enrolled 19 July 2012. Results are reported as of the data cut-off date of 5 February 2013.

Participant flow — Overall Study
MilestoneCetuximabPanitumumab
Started504506
Received treatment500499
Completed7885
Not completed426421
Withdrew: Ineligibility determined20
Withdrew: Withdrawal by subject1920
Withdrew: Lost to follow-up1417
Withdrew: Death391384

Outcome measures

PrimaryOverall Survival

Overall survival is the time from the date of randomization until the date of death. Participants who had not died by the analysis data cut-off date were censored at their last contact date.

Time frame:
From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.
Reported as:
Median · months
Overall Survival
monthsCetuximabPanitumumab
Overall Survival10.0 (9.3 to 11.0)10.4 (9.4 to 11.6)
Statistical analysis
  • Cetuximab vs Panitumumab · Stratified cox proportional hazard ratio: 0.966 · 95% CI 0.839 to 1.113Hazard ratio is presented as panitumumab : cetuximab. A value \< 1.0 indicates a lower average event rate and longer time to event for panitumumab relative to cetuximab.
  • Cetuximab vs Panitumumab · Asymptotic standard normal test · p = 0.0007 (A synthesis approach with an asymptotic standard normal test statistic) · Normal score: -3.19
SecondaryProgression-free Survival

Progression free survival (PFS) is the time from the date of randomization to the date of disease progression per the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or death. Participants alive and not meeting criteria for progression by the analysis data cut-off date were censored at their last evaluable disease assessment date. Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study based on all target lesions recorded since the treatment started (the sum must also demonstrate an absolute increase of at least 5 mm), or unequivocal progression of existing non-target lesions, or any new lesions.

Time frame:
From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.
Reported as:
Median · months
Progression-free Survival
monthsCetuximabPanitumumab
Progression-free Survival4.4 (3.2 to 4.8)4.1 (3.2 to 4.8)
SecondaryObjective Response

Objective response is either a complete response (CR) or partial response (PR) per RECIST version 1.1. All participants that did not meet the criteria for an objective response by the analysis cut-off date were considered non-responders. CR: Disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and disappearance of all non-target lesions, and no new lesions. PR: Disappearance of all target lesions, persistence of one or more non-target lesions not qualifying for either CR or progressive disease, or, at least a 30% decrease in the sum of diameters of target lesions with no unequivocal progression of existing non-target lesions and no new lesions.

Time frame:
From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.
Reported as:
Number · percentage of participants
Objective Response
percentage of participantsCetuximabPanitumumab
Objective Response19.79 (16.34 to 23.62)22.02 (18.41 to 25.97)
Statistical analysis
  • Cetuximab vs Panitumumab · Odds ratio (or): 1.15 · 95% CI 0.83 to 1.58Common treatment odds ratio stratified by geographic region (North America, western Europe and Australia vs rest of world) and ECOG performance status (0 or 1 vs 2).
SecondaryDuration of Response

Duration of response (DOR), calculated only for those participants with an objective response, is the time from first objective response to disease progression per the RECIST v1.1 or death. Participants not meeting criteria for progression or who died by the analysis data cutoff date were censored at their last evaluable disease assessment date.

Time frame:
From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.
Reported as:
Median · months
Duration of Response
monthsCetuximabPanitumumab
Duration of Response5.4 (3.8 to 5.5)3.8 (3.7 to 4.8)
SecondaryTime to Response

Time to response (TTR), calculated for those participants with an objective response, is defined as the time from the randomization date to the date of first objective response.

Time frame:
From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.
Reported as:
Median · months
Time to Response
monthsCetuximabPanitumumab
Time to Response2.6 (1.2 to 3.1)1.5 (1.2 to 3.0)
SecondaryTime to Treatment Failure

Time to treatment failure (TTF) is the time from randomization date to date that the decision was made to end the treatment period for any reason; participants who remained in the treatment period at the time of analysis were censored at the date of the last on-study assessment.

Time frame:
From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.
Reported as:
Median · months
Time to Treatment Failure
monthsCetuximabPanitumumab
Time to Treatment Failure3.3 (3.2 to 3.9)3.4 (3.2 to 4.6)
SecondaryChange From Baseline in EuroQOL 5 Dimension (EQ-5D) Health State Index Score

The EQ-5D is a standardized instrument for use as a generic measure of health outcome. The health state index measures the following 5 health dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension contains 3 levels of response to reflect degree of problems participants have experienced: no problem (1), some problem (2) and extreme problems (3). The health states for each respondent are converted into a single index number using a specified set of weights. Resulting scores can range from 1.0 and -0.594. A higher score indicates a more preferred health status with 1.0 representing perfect health and 0 representing death. Negative scores are possible and represent health states regarded as less preferable than death (0). Repeated measures mixed model includes treatment, geographic region, ECOG score, assessment week, and treatment by assessment week interaction as fixed effects, and participants a random effect.

Time frame:
From Study Day 1 through the last day of treatment or disease progression, up to Week 85.
Reported as:
Least squares mean · scores on a scale
Change From Baseline in EuroQOL 5 Dimension (EQ-5D) Health State Index Score
scores on a scaleCetuximabPanitumumab
Change From Baseline in EuroQOL 5 Dimension (EQ-5D) Health State Index Score-0.0341 (-0.0806 to 0.0123)-0.0216 (-0.0691 to 0.0260)
Statistical analysis
  • Cetuximab vs Panitumumab · Ls mean difference: 0.0126 · 95% CI -0.0353 to 0.0605A positive difference between the treatment groups favors the panitumumab group.
SecondaryChange From Baseline in EuroQOL 5 Dimension (EQ-5D) Visual Analog Scale (VAS)

The EQ-5D is a standardized instrument for use as a generic measure of health outcome. The VAS asks respondents to rate their present health status on a 0 - 100 scale, with 0 labeled as "Worst imaginable health state" and 100 labeled as "Best imaginable health state." The VAS score is determined by observing the point at which the participant's hand drawn line intersects the scale.

Time frame:
From Study Day 1 through the last day of treatment or disease progression, up to Week 85.
Reported as:
Least squares mean · scores on a scale
Change From Baseline in EuroQOL 5 Dimension (EQ-5D) Visual Analog Scale (VAS)
scores on a scaleCetuximabPanitumumab
Change From Baseline in EuroQOL 5 Dimension (EQ-5D) Visual Analog Scale (VAS)3.9782 (0.8842 to 7.0722)2.3037 (-0.8532 to 5.4605)
Statistical analysis
  • Cetuximab vs Panitumumab · Ls mean difference: -1.6745 · 95% CI -4.9331 to 1.5841A positive difference between the treatment groups favors the panitumumab group.
SecondaryChange From Baseline in National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Colorectal Symptom Index (NCCN FCSI ) Symptoms Score

The FCSI consists of 9 questions comprising the most important symptoms associated with colorectal cancer, including energy, pain, weight, diarrhea, nausea, swelling or cramps in the stomach area, appetite, ability to enjoy life, and overall quality of life. The 9 questions are combined in three algorithms to provide information for 3 domains: colorectal cancer symptoms, physical well-being, and functional well-being. Each of the 9 items are scored from "0" to "4" representing "Not at All" through to "Very Much True". The raw score for all items is transformed to a 0-100 scale, and the average for each of the 3 subscales is calculated; high scores illustrate an improved state (e.g. able to enjoy life more).

Time frame:
From Study Day 1 through the last day of treatment or disease progression, up to Week 85.
Reported as:
Least squares mean · scores on a scale
Change From Baseline in National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Colorectal Symptom Index (NCCN FCSI ) Symptoms Score
scores on a scaleCetuximabPanitumumab
Change From Baseline in National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Colorectal Symptom Index (NCCN FCSI ) Symptoms Score2.0101 (-1.1477 to 5.1679)3.0473 (-0.1782 to 6.2728)
Statistical analysis
  • Cetuximab vs Panitumumab · Ls mean difference: 1.0372 · 95% CI -2.3267 to 4.4010A positive difference between the treatment groups favors the panitumumab group.
SecondaryChange From Baseline in NCCN FCSI Physical Well-being Scale Score

The FCSI consists of 9 questions comprising the most important symptoms associated with colorectal cancer, including energy, pain, weight, diarrhea, nausea, swelling or cramps in the stomach area, appetite, ability to enjoy life, and overall quality of life. The 9 questions are combined in three algorithms to provide information for 3 domains: colorectal cancer symptoms, physical well-being, and functional well-being. Each of the 9 items are scored from "0" to "4" representing "Not at All" through to "Very Much True". The raw score for all items is transformed to a 0-100 scale, and the average for each of the 3 subscales is calculated; high scores illustrate an improved state (e.g. able to enjoy life more).

Time frame:
From Study Day 1 through the last day of treatment or disease progression, up to Week 85.
Reported as:
Least squares mean · scores on a scale
Change From Baseline in NCCN FCSI Physical Well-being Scale Score
scores on a scaleCetuximabPanitumumab
Change From Baseline in NCCN FCSI Physical Well-being Scale Score1.8778 (-1.5524 to 5.3080)2.4614 (-1.0442 to 5.9670)
Statistical analysis
  • Cetuximab vs Panitumumab · Ls mean difference: 0.5836 · 95% CI -3.0269 to 4.1941A positive difference between the treatment groups favors the panitumumab group.
SecondaryChange From Baseline in NCCN FCSI Functional Well-being Scale Score

The FCSI consists of 9 questions comprising the most important symptoms associated with colorectal cancer, including energy, pain, weight, diarrhea, nausea, swelling or cramps in the stomach area, appetite, ability to enjoy life, and overall quality of life. The 9 questions are combined in three algorithms to provide information for 3 domains: colorectal cancer symptoms, physical well-being, and functional well-being. Each of the 9 items are scored from "0" to "4" representing "Not at All" through to "Very Much True". The raw score for all items is transformed to a 0-100 scale, and the average for each of the 3 subscales is calculated; high scores illustrate an improved state (e.g. able to enjoy life more).

Time frame:
From Study Day 1 through the last day of treatment or disease progression, up to Week 85.
Reported as:
Least squares mean · scores on a scale
Change From Baseline in NCCN FCSI Functional Well-being Scale Score
scores on a scaleCetuximabPanitumumab
Change From Baseline in NCCN FCSI Functional Well-being Scale Score1.3567 (-4.1564 to 6.8697)1.1569 (-4.4887 to 6.8025)
Statistical analysis
  • Cetuximab vs Panitumumab · Ls mean difference: -0.1998 · 95% CI -6.0093 to 5.6098A positive difference between the treatment groups favors the panitumumab group.
SecondaryNumber of Participants With Adverse Events (AEs)

Serious adverse events include any event that is fatal, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or other significant medical hazard. Treatment-related AEs are those the investigator considered as a reasonable possibility to have been caused by study drug.

Time frame:
From the day of the first dose of study therapy through 30 days since the last dose. Maximum time on study treatment was 130 weeks.
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsCetuximabPanitumumab
Any adverse event (AE)494485
Serious adverse events169151
Leading to discontinuation of study drug6169
Any treatment-related adverse event (TRAE)459437
Treatment-related serious adverse event2225
TRAE leading to discontinuation of study drug1514

Adverse events

Collected over Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cetuximab—169/503 (33.6%)474/503 (94.2%)
Panitumumab—151/496 (30.4%)459/496 (92.5%)
Most frequent serious events
Showing 10 of 234
Most frequent serious events
EventCetuximabPanitumumab
Colorectal cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)14/5037/496
Abdominal painGastrointestinal disorders13/50310/496
Intestinal obstructionGastrointestinal disorders8/50312/496
VomitingGastrointestinal disorders5/50312/496
Colorectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)10/5037/496
Urinary tract infectionInfections and infestations7/5039/496
DiarrhoeaGastrointestinal disorders8/5036/496
PyrexiaGeneral disorders8/5033/496
PneumoniaInfections and infestations7/5032/496
AnaemiaBlood and lymphatic system disorders3/5036/496
Most frequent other events
Showing 10 of 31
Most frequent other events
EventCetuximabPanitumumab
RashSkin and subcutaneous tissue disorders257/503249/496
Dermatitis acneiformSkin and subcutaneous tissue disorders136/503138/496
HypomagnesaemiaMetabolism and nutrition disorders89/503134/496
DiarrhoeaGastrointestinal disorders87/50388/496
PruritusSkin and subcutaneous tissue disorders88/50383/496
FatigueGeneral disorders85/50372/496
Dry skinSkin and subcutaneous tissue disorders79/50383/496
Decreased appetiteMetabolism and nutrition disorders77/50369/496
ParonychiaInfections and infestations75/50358/496
Abdominal painGastrointestinal disorders74/50352/496

Baseline characteristics

Age, Continuous
Age, Continuous(years)CetuximabPanitumumabTotal
Mean60.2 ± 11.259.6 ± 10.959.9 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)CetuximabPanitumumabTotal
Female183187370
Male321319640
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)CetuximabPanitumumabTotal
Asian230225455
Black or African American426
Hispanic or Latino7613
Japanese011
Other325
White or Caucasian260270530
Geographic region
Geographic region(participants)CetuximabPanitumumabTotal
North America, Western Europe and Australia158158316
Rest of World346348694
Eastern Cooperative Oncology Group (ECOG) performance status
Eastern Cooperative Oncology Group (ECOG) performance status(participants)CetuximabPanitumumabTotal
Grade 0165155320
Grade 1299309608
Grade 2404282
08

Study locations

152 sites
  • Research Site
    Stockton, California 95204, United States
  • Research Site
    Boynton Beach, Florida 33426, United States
  • Research Site
    Wichita, Kansas 67214, United States
  • Research Site
    Temple, Texas 76508, United States
  • Research Site
    Ogden, Utah 84403, United States
  • Research Site
    Liverpool, New South Wales 2170, Australia
  • Research Site
    St Leonards, New South Wales 2065, Australia
  • Research Site
    Wahroonga, New South Wales 2076, Australia
  • Research Site
    Wollongong, New South Wales 2500, Australia
  • Research Site
    Woodville South, South Australia 5011, Australia
  • Research Site
    Ballarat, Victoria 3350, Australia
  • Research Site
    Box Hill, Victoria 3128, Australia
  • Research Site
    Epping, Victoria 3076, Australia
  • Research Site
    Footscray, Victoria 3011, Australia
  • Research Site
    Heidelberg, Victoria 3084, Australia
  • Research Site
    Parkville, Victoria 3050, Australia
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Sofia, 1527, Bulgaria
  • Research Site
    Sofia, 1784, Bulgaria
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Research Site
    Guangzhou, Guangdong 510060, China
  • Research Site
    Guangzhou, Guangdong 510180, China
  • Research Site
    Guangzhou, Guangdong 510280, China
  • Research Site
    Guangzhou, Guangdong 515515, China
  • Research Site
    Harbin, Heilongjiang 150040, China
  • Research Site
    Changsha, Hunan 410013, China
  • Research Site
    Nanjing, Jiangsu 210002, China
  • Research Site
    Changchun, Jilin 130012, China
  • Research Site
    XI An, Shaanxi 710061, China
  • Research Site
    Shanghai, Shanghai 200092, China
  • Research Site
    Chengdu, Sichuan 610041, China
  • Research Site
    Chongqing, Sichuan 400038, China
  • Research Site
    Hangzhou, Zhejiang 310009, China
  • Research Site
    Hangzhou, Zhejiang 310016, China
  • Research Site
    Beijing, 100021, China
  • Research Site
    Beijing, 100071, China
  • Research Site
    Beijing, 100142, China
  • Research Site
    Shanghai, 200003, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, 200080, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Horovice, 268 31, Czechia
  • Research Site
    Nova Ves pod Plesi, 262 04, Czechia
  • Research Site
    Olomouc, 775 20, Czechia
  • Research Site
    Praha 10, 100 34, Czechia
  • Research Site
    Pribram, 261 01, Czechia
  • Research Site
    Znojmo, 669 02, Czechia
  • Research Site
    Besançon Cedex, 25030, France
  • Research Site
    Montbéliard, 25200, France
  • Research Site
    Saint Brieuc, 22015, France
  • Research Site
    Saint Herblain, 44800, France
  • Research Site
    Villejuif cedex, 94805, France
  • Research Site
    Kowloon, Hong Kong
  • Research Site
    New Territories, Hong Kong
  • Research Site
    Hyderabad, Andhra Pradesh 500 024, India
  • Research Site
    Hyderabad, Andhra Pradesh 500 034, India
  • Research Site
    Kochi, Kerala 682 304, India
  • Research Site
    Ahmednagar, Maharashtra 413 736, India
  • Research Site
    Nagpur, Maharashtra 440 012, India
  • Research Site
    Nashik, Maharashtra 422 004, India
  • Research Site
    Nashik, Maharashtra 422 005, India
  • Research Site
    Pune, Maharashtra 411 004, India
  • Research Site
    Jaipur, Rajasthan 302 013, India
  • Research Site
    Chennai, Tamil Nadu 600 018, India
  • Research Site
    Kolkata, West Bengal 700 016, India
  • Research Site
    Beer Sheva, 64239, Israel
  • Research Site
    Jerusalem, 91031, Israel
  • Research Site
    Kfar Saba, 44281, Israel
  • Research Site
    Ramat Gan, 52621, Israel
  • Research Site
    Rehovot, 76100, Israel
  • Research Site
    Ancona, 60131, Italy
  • Research Site
    Cesena, 47023, Italy
  • Research Site
    Cremona, 26100, Italy
  • Research Site
    Faenza RA, 48018, Italy
  • Research Site
    Genova, 16132, Italy
  • Research Site
    Lugo, 48022, Italy
  • Research Site
    Meldola FC, 47014, Italy
  • Research Site
    Ravenna, 48100, Italy
  • Research Site
    Rimini, 47900, Italy
  • Research Site
    Torino, 10126, Italy
  • Research Site
    Goyang-si, Gyeonggi-do, 410-769, Korea, Republic of
  • Research Site
    Seoul, 110-744, Korea, Republic of
  • Research Site
    Seoul, 120-752, Korea, Republic of
  • Research Site
    Seoul, 135-710, Korea, Republic of
  • Research Site
    Seoul, 136-705, Korea, Republic of
  • Research Site
    Seoul, 138-736, Korea, Republic of
  • Research Site
    Daugavpils, 5417, Latvia
  • Research Site
    Riga, 1002, Latvia
  • Research Site
    Riga, 1079, Latvia
  • Research Site
    Kaunas, 50009, Lithuania
  • Research Site
    Vilnius, 08660, Lithuania
  • Research Site
    Kota Bharu, Kelantan 16150, Malaysia
  • Research Site
    Kota Kinabalu, Sabah 88996, Malaysia
  • Research Site
    Kuala Lumpur, Wilayah Persekutuan 56000, Malaysia
  • Research Site
    Kuala Lumpur, Wilayah Persekutuan 59100, Malaysia
  • Research Site
    Rotterdam, 3000 CA, Netherlands
  • Research Site
    Lima, 13, Peru
  • Research Site
    Lima, 34, Peru
  • Research Site
    Lima, Lima 27, Peru

Showing the first 100 of 152 sites across 29 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Price T, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Guan X, Peeters M. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. Eur J Cancer. 2016 Nov;68:51-59. doi: 10.1016/j.ejca.2016.08.010. Epub 2016 Oct 5. PubMed 27716478 ↗
  • Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Zhang K, Murugappan S, Sidhu R. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014 May;15(6):569-79. doi: 10.1016/S1470-2045(14)70118-4. Epub 2014 Apr 14. PubMed 24739896 ↗
  • Kim TW, Peeters M, Thomas A, Gibbs P, Hool K, Zhang J, Ang AL, Bach BA, Price T. Impact of Emergent Circulating Tumor DNA RAS Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer. Clin Cancer Res. 2018 Nov 15;24(22):5602-5609. doi: 10.1158/1078-0432.CCR-17-3377. Epub 2018 Jun 13. PubMed 29898991 ↗
  • Peeters M, Price T, Boedigheimer M, Kim TW, Ruff P, Gibbs P, Thomas A, Demonty G, Hool K, Ang A. Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study. Clin Cancer Res. 2019 Feb 15;25(4):1216-1225. doi: 10.1158/1078-0432.CCR-18-2072. Epub 2018 Nov 28. PubMed 30487126 ↗
  • Price T, Ang A, Boedigheimer M, Kim TW, Li J, Cascinu S, Ruff P, Satya Suresh A, Thomas A, Tjulandin S, Peeters M. Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy. Cancer Biol Ther. 2020 Oct 2;21(10):891-898. doi: 10.1080/15384047.2020.1798695. Epub 2020 Oct 7. PubMed 33026965 ↗
  • Taniguchi H, Yamanaka T, Sakai D, Muro K, Yamazaki K, Nakata S, Kimura H, Ruff P, Kim TW, Peeters M, Price T. Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G. Cancers (Basel). 2020 Jun 28;12(7):1715. doi: 10.3390/cancers12071715. PubMed 32605298 ↗
  • Graham CN, Maglinte GA, Schwartzberg LS, Price TJ, Knox HN, Hechmati G, Hjelmgren J, Barber B, Fakih MG. Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy. Clin Ther. 2016 Jun;38(6):1376-1391. doi: 10.1016/j.clinthera.2016.03.023. Epub 2016 Apr 13. PubMed 27085587 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2010 to primary completion in Feb 2013, 36 months.

Results were first posted in Mar 2014, 1 year 1 month after primary completion.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 36 months is below that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2009
First posted
Oct 26, 2009
StartActual
Feb 2, 2010
Primary completionActual
Feb 5, 2013
CompletionActual
Mar 7, 2017
Results first posted
Mar 24, 2014
Last update
Sep 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01001377
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 26, 2009
Start date
Feb 2, 2010
Primary completion
Feb 5, 2013
Completion
Mar 7, 2017
Results posted
Mar 24, 2014
Last update
Sep 21, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Panitumumab

Start the discussion